The undersigned organizations, on behalf of tens of millions of Americans with serious illnesses, chronic conditions, and disabilities, are submitting this formal comment pertaining to your recent Notice of Proposed Rule Making. While we appreciate the Centers for Medicare and Medicaid Services (CMS) prioritizing efforts towards expanding access to care and lowering prescription drug costs, we are concerned that the proposed rule contains a provision that will increase barriers to access of care and put those individuals struggling with chronic and debilitating disease at risk for further health complications.
Categories
- Access
- Advocacy
- California
- Comment Letters
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- FDA
- Featured
- Featured Action
- Federal Issues
- Health Insurance
- Health Policy
- ICER
- Illinois
- Issues
- Letters Submitted
- Letters Supported
- Massachusetts
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- Prescription Drugs
- Press Releases
- Public Statement
- QALY
- State Issues
- Statements
- Step Therapy
- Surprise Billing
- Uncategorized
- Value Based Insurance Design
- Value Frameworks
- Virtual Advocacy Chat
Tags
21st Century Cures Act
340B
Access to Care
Advocacy
Alzheimer's
Biden Administration
biosimilars
Cancer
cms
Copay Accumulators
copay assistance
COVID-19 Vaccine
drug costs
Drug Manufacturing
Drug Pricing
drug rebate
fail first
FDA
Gene Therapies
H.R.3
Health Insurance
hospital bills
HR 3708
hsa
ICER
Insurance design
Joe Biden
medicare Part B
medicare part D
Mental Health
Nonmedical Switching
open enrollment
Out of Pocket Costs
PBM
PBMs
pharmacy benefit managers
Price Transparency
Prior Authorization
QALY
Rare Disease
Right to Repair
Step Therapy
Telehealth
transparency
Value Framework
Recent Posts
- Wilcox: A Bipartisan Victory for Patients to Ban Discriminatory Metrics Congressional Subcommittee Agrees: Patient Lives are WORTH IT
- Patients Rising Now Submits Comments on Patient Rights to United States Patent and Trademark Office
- New Harris Poll: FDA Should Regulate All Medical Device Service and Repair
- Patient Impact Report: Discrimination Faced by Patients with Rare Diseases
- Are States Prepared for the End of COVID-19 Emergency Declarations?